Earnout Definition: What an Earnout Is, How It Works, and What to Watch For

Earnout definition: an earnout is a contractual mechanism in a merger or acquisition (M&A) deal where the buyer pays a portion of the purchase price contingent on the acquired company hitting specified post-closing performance targets over a defined measurement period. Instead of paying 100% of the agreed price at closing, the buyer pays a base amount up front and the remaining amount only if the business hits revenue, EBITDA, retention, or milestone targets in the following 1 to 3 years. If targets are missed, that contingent portion is reduced or forfeited.
The terms “earn out,” “earn-out,” and “earnout” all refer to the same instrument; the spelling is not standardized by the American Bar Association (ABA) or the Securities and Exchange Commission (SEC), and both forms appear in primary deal documents filed on SEC EDGAR. According to the SRS Acquiom 2024 M&A Deal Terms Study, roughly 27% of private-target acquisitions closed in 2023 contained an earnout, the highest share recorded since the study began tracking the metric in 2012.
This guide covers the earnout structure, the literal meaning of the term, five worked examples with real dollar figures, the four main payout structures used in practice, metric selection, the accounting drift problem that drives 18 to 22% of earnouts into dispute, legal protections sellers should demand, tax treatment under Internal Revenue Code (IRC) Sections 453 and 483, current 2024 and 2025 trends, and how earnouts compare to holdbacks, seller notes, and rollover equity. If you want the deeper mechanics, see the parent guide on earn-outs at ctacquisitions.com and the companion piece on how to negotiate an earnout.
TL;DR: Earnout Definition in 60 Seconds
Three bullets that cover most of what a deal lawyer or M&A banker will tell a seller in the first conversation about earnouts.
- What it is: An earnout is a deferred portion of the purchase price in an M&A transaction, paid only if the acquired business hits specific post-closing financial or operational targets within an agreed measurement period.
- Why it exists: It bridges a valuation gap. The seller believes the business will perform well; the buyer is unwilling to underwrite that performance until it actually shows up. The earnout shifts the future-performance risk from the buyer back to the seller.
- What to watch for: Post-closing operational control sits with the buyer. If the metric is EBITDA-based, the buyer can legally compress the earnout by changing accounting policies, increasing allocations of corporate overhead, or deferring revenue recognition. Roughly 18 to 22% of earnouts end in dispute, per SRS Acquiom 2024.
One-sentence structure: Buyer pays $X at closing plus up to $Y additional over a 1 to 3 year measurement period, calculated as a function of a specified metric (revenue, EBITDA, customer retention, or a milestone like FDA approval), subject to a cap, sometimes a floor, and a written calculation methodology.
Worked example (the simplest version): SaaS company sells for $50M at closing plus up to $25M earnout, paid only if Year 3 annual recurring revenue (ARR) exceeds $40M. If ARR comes in at $40M or above, seller receives the full $25M. If ARR comes in at $30M (75% of target on a graduated scale), seller receives $18.75M. If ARR comes in below $25M, seller receives $0. Total possible consideration: $75M. Total guaranteed consideration: $50M.
The Literal Earnout Meaning: Where the Word Comes From
The “earnout meaning” is captured directly in the construction of the word itself. The seller “earns out” the remaining purchase price by delivering the performance promised during sale negotiations. The buyer is effectively saying: you told me this business is worth $75M; I will pay you $50M today, and I will pay the other $25M out to you as you earn it.
The term entered M&A vocabulary in the United States in the late 1960s and early 1970s, when conglomerate acquirers began using contingent consideration to acquire smaller founder-led businesses where the founder’s continued involvement was central to future performance. The earliest documented commercial uses of “earn-out” in a deal context appear in The Wall Street Journal archived coverage of acquisitions in the late 1960s, and the structure was widely adopted by accounting and law firms by the mid-1970s. Investopedia’s earnout entry traces the structure to that era as well.
Neither the ABA Mergers and Acquisitions Committee nor the SEC has mandated a single spelling. The ABA’s Model Stock Purchase Agreement uses “Earnout” as the defined term in body text but accepts “Earn-Out” in older versions. EDGAR filings from large law firms such as Skadden Arps, Wachtell Lipton, and Kirkland & Ellis alternate between all three forms. The Financial Accounting Standards Board (FASB), in ASC 805 (Business Combinations), uses “contingent consideration” as the technical accounting term and reserves “earnout” for plain-English explanation.
For practical purposes, “earn out definition” and “earnout definition” return identical search intent and identical legal meaning. Drafters typically pick one form and remain consistent throughout a given agreement. When a definition section in a purchase agreement says “Earnout Payment has the meaning set forth in Section 2.7,” the spelling in that defined term governs that contract only; it is not portable to other agreements.
Earnout Structure: The 5 Standard Components
Every earnout, regardless of industry or deal size, contains the same five structural components. A purchase agreement that omits any of them is incomplete and will almost certainly produce litigation. The components below appear in the order they are typically drafted into a stock or asset purchase agreement (SPA / APA).
| Component | What it specifies | Typical range or example |
|---|---|---|
| Total earnout pool | Maximum dollar amount the buyer will pay if the seller maxes out the earnout | 20% to 50% of total deal value; commonly $5M to $200M depending on deal size |
| Performance metric | The financial or operational variable that drives the payout calculation | Revenue, EBITDA, gross margin, ARR, unit count, customer retention, FDA milestone |
| Measurement period | The post-closing window over which the metric is measured | 1 year (short), 2 to 3 years (most common), 4 to 5 years (long, pharma) |
| Payout schedule | How and when the earned amount is paid to the seller | Single payment at end, annual installments, milestone-triggered |
| Cap and floor | Maximum payable and minimum guaranteed amounts | Cap is always present; floor is rare but appears in roughly 12% of deals per SRS Acquiom 2024 |
Total earnout pool
The total earnout pool is the ceiling. If the seller delivers above-target performance, this is the most they can receive. In the 2024 SRS Acquiom dataset, the median earnout pool was 26% of total deal consideration, with a long tail of pharma and biotech deals where the contingent portion exceeded 100% of base consideration (i.e., a $50M base with a $100M milestone earnout for FDA approval).
Performance metric
The metric is the most negotiated component. Revenue is cleanest because it is hardest to manipulate. EBITDA is most common in private equity (PE) deals but most game-able by the buyer. Customer retention is common in subscription and services businesses. Milestones (FDA approval, regulatory clearance, key contract execution) are typical in pharma, biotech, and government services. See the dedicated metric selection section below.
Measurement period
Per SRS Acquiom 2024, the median earnout measurement period in 2023 was 24 months, up from 18 months in 2019. Pharma milestone earnouts can run 5 to 10 years tied to specific regulatory events. Shorter periods favor the buyer (less time for the metric to drift); longer periods favor the seller (more chances to deliver).
Payout schedule
Payout schedules range from a single payment at the end of the measurement period (worst for seller; one chance to hit the number) to annual interim payments (better for seller; locks in tranches) to milestone-triggered (pharma standard; payment on event, not on date).
Cap and floor
The cap is universal. The floor (a minimum guaranteed amount paid regardless of performance) is rare and appears mainly when the seller has heavy negotiating power or when the buyer needs the seller’s continued employment cooperation. In the 2024 SRS Acquiom data, roughly 12% of earnouts had a floor, typically in the 20% to 40% of cap range.
Why Earnouts Exist: The Valuation Gap Problem
Earnouts solve a specific problem: the seller and the buyer disagree about how much the business is worth. The disagreement is almost always rooted in differing views of the future, not the past. The seller sees a hockey-stick projection and prices the business off the projected EBITDA in Year 2 or Year 3. The buyer sees execution risk, customer concentration, founder dependency, regulatory uncertainty, or unproven scaling, and prices the business off trailing twelve months (TTM) EBITDA.
If the seller wants $100M based on projected $20M EBITDA at a 5x forward multiple, and the buyer will only pay $70M based on $14M TTM EBITDA at a 5x trailing multiple, the deal is $30M apart and dead. The earnout reopens the deal: buyer pays $70M at closing, and pays the seller an additional amount of up to $30M over 2 years if EBITDA actually grows into the seller’s projection. If the seller was right, the seller gets the $100M they wanted. If the seller was wrong, the buyer only paid for what they actually got.
This structure is most common in the following scenarios, all of which appear repeatedly in Pepperdine Private Capital Markets Surveys and in SRS Acquiom data.
- Founder-dependent revenue: The business is materially the founder. An earnout ties part of the price to whether the founder can transfer relationships.
- Customer concentration risk: One customer is 30% or more of revenue. The earnout protects the buyer if that customer churns post-closing.
- Hockey-stick projections: The seller is forecasting 50% or higher growth without strong historical evidence. The earnout requires the seller to prove the curve.
- Regulatory pending: Pharma, medical device, defense, fintech. The earnout pays only on regulatory clearance.
- Synergy dependent valuation: The buyer is paying a premium based on synergies. The earnout ties part of the premium to actually realizing them.
- Distressed or recently turned around: The business is fresh off a turnaround. The earnout requires the new performance to stick.
5 Typical Earnout Examples with Real Dollar Figures
The clearest way to understand earnouts is to see the dollars worked out. The five examples below are anonymized but reflect the structure of real deals reported in SEC EDGAR filings and in published M&A casework from Bain & Company, BCG, and McKinsey M&A insights.
| Deal type | Cash at close | Earnout cap | Metric and target | Measurement period |
|---|---|---|---|---|
| SaaS acquisition | $50M | $25M | Year 3 ARR > $40M | 36 months |
| Professional services rollup | $20M | $5M | Customer retention > 90% in Year 2 | 24 months |
| Pharma milestone | $100M | $200M | FDA approval of lead candidate by Year 5 | 60 months |
| Retail or franchise | $30M | $10M | YoY revenue growth > 15% in Years 1 and 2 | 24 months |
| Tech acqui-hire | $80M | $40M | Key employee retention at month 24 | 24 months |
Example 1: SaaS deal, $50M base plus $25M earnout
Buyer pays $50M at closing for a vertical SaaS business doing $25M ARR. Buyer believes ARR will grow to roughly $32M to $35M without significant investment. Seller believes ARR will reach $45M with continued go-to-market spend. The earnout pays $25M if Year 3 ARR exceeds $40M, with a graduated sliding scale: at $30M ARR the seller receives $12.5M (50% of cap); at $35M ARR the seller receives $18.75M (75% of cap); at $40M or above the seller receives the full $25M.
Example 2: Services deal, $20M base plus $5M earnout
Buyer acquires a managed services firm with $40M revenue and significant customer concentration in the top five accounts. Earnout pays $5M only if the buyer retains at least 90% of acquired customers (measured as Year 2 revenue from Year 0 customers) at the 24-month mark. Below 80% retention, seller receives $0. Between 80% and 90%, seller receives a linear scale of $0 to $5M.
Example 3: Pharma milestone, $100M base plus $200M earnout
Large pharma acquires a clinical-stage biotech for $100M cash plus up to $200M in milestone payments: $50M on Phase 3 trial initiation, $75M on FDA New Drug Application (NDA) acceptance, and $75M on FDA approval. Earnout is purely event-driven; no revenue or EBITDA metric. This structure dominates clinical-stage biotech M&A; see FDA drug approval process documentation.
Example 4: Retail deal, $30M base plus $10M earnout
PE firm acquires a multi-unit retail concept. Earnout pays $5M if Year 1 same-store revenue growth exceeds 15% and another $5M if Year 2 growth also exceeds 15%. Cliff structure: if growth is 14.9%, seller receives $0 for that year. Cliff structures are aggressive against the seller and require careful drafting of how “same-store” is measured (new store openings, store closures, and store renovations all create disputes).
Example 5: Tech acqui-hire, $80M base plus $40M earnout
Strategic buyer acquires a 40-person engineering team. The valuation is mostly in the people. Earnout pays $40M if the founder and the top 10 engineers (defined by name in a schedule to the SPA) remain employed at month 24. This is technically a “retention earnout” and triggers ordinary income tax treatment for the seller rather than capital gains, per IRC and case law discussed in the tax section below.
Earnout Payout Structures: The 4 Main Types
Once the metric and measurement period are set, the next decision is how the payout is shaped. There are four standard structures, each with different risk profiles for the seller and the buyer.
| Structure | How it pays | Risk profile | Best for |
|---|---|---|---|
| Single-trigger (all-or-nothing) | Hit target = 100% of cap; miss target = $0 | Highest variance for seller | Binary milestones (FDA approval, contract award) |
| Sliding scale (graduated) | 0 to 100% of cap based on percentage of target hit | Most balanced; standard for revenue and EBITDA earnouts | Financial-metric earnouts where partial credit is fair |
| Multi-metric (combination) | Combined revenue, EBITDA, and retention all need to clear | Compounds difficulty for seller | Buyer-favorable structures where multiple risks are present |
| Cliff (threshold) | Above threshold = full pool; below = $0; no partial credit | Aggressive against seller; rare in negotiated deals | Situations where partial performance is no value to buyer |
Single-trigger earnouts
The earnout pays in full only if a binary condition is satisfied. Most pharma milestone earnouts are single-trigger by structure: the FDA either approves the drug or it does not. Single-trigger earnouts are clean to administer but produce zero versus full payouts with no middle ground.
Sliding scale earnouts
The earnout pays a graduated percentage of the cap based on how close the seller gets to the target. A common formula: payout equals cap multiplied by (actual / target), capped at 100% of cap and floored at 0%. Per SRS Acquiom 2024, sliding scale is the structure used in roughly 58% of revenue and EBITDA earnouts.
Multi-metric earnouts
Two or more metrics must each clear their own threshold. Example: revenue must exceed $50M AND EBITDA must exceed $10M AND customer retention must exceed 85%. Each constraint is a separate point of failure for the seller, which is why this structure is buyer-favorable.
Cliff earnouts
The seller receives the full earnout pool if performance is above the threshold and $0 if below. Cliffs are aggressive and typically only appear when the buyer would have walked from the deal without the cliff (the buyer is unwilling to pay partial earnout for partial performance).
Earnout Metric Selection: Why Revenue Is Cleanest and EBITDA Is Hardest to Game
The metric chosen for an earnout determines who controls the outcome. The further the metric is from gross sales and the closer it is to net income, the more the buyer’s post-closing accounting decisions affect the result. The table below summarizes the standard tradeoffs.
| Metric | Gameability by buyer | When appropriate | Notes |
|---|---|---|---|
| Revenue | Low | Most general-purpose earnouts | Cleanest; harder to compress through accounting |
| ARR (annual recurring revenue) | Low to medium | SaaS, subscription businesses | Requires written definition of “recurring” |
| Gross margin | Medium | Manufacturing, distribution | Subject to cost-of-goods reallocation |
| EBITDA | High | PE deals where buyer wants risk shifted | Subject to overhead allocation and accounting changes |
| Net income | Very high | Rare; usually a drafting error | Below the EBITDA line is fully buyer-controlled |
| Customer retention | Medium | Services, SaaS | Requires unambiguous definition of “retained customer” |
| Milestone (FDA, contract, etc.) | Low to medium | Pharma, biotech, govcon | Single-trigger; binary outcomes |
Revenue: Hardest for the buyer to compress because revenue recognition is governed by ASC 606 and audited by the buyer’s external auditors. The buyer cannot easily defer revenue from one period to another without auditor pushback. A revenue-based earnout is the seller’s default ask.
EBITDA: Most game-able. The buyer controls cost classification, overhead allocation from the parent, capital expenditure timing (which affects depreciation and therefore is “above” or “below” the EBITDA line depending on definition), and operating expense decisions. Sellers should never accept EBITDA without a long, written list of pre-agreed adjustments and a no-change-in-accounting-policy covenant.
Customer retention: Standard in services. Requires a precise definition of “retained” (still purchasing? still paying the same dollar amount? same product mix?). Disputes around customer retention usually turn on how the buyer reorganized the customer base post-closing.
Milestone: Cleanest because outcomes are typically binary and externally verified (FDA approval, contract award, regulatory clearance). The risk is timing: buyers can delay regulatory filings or contract bids to push milestones past the measurement period.
The Accounting Drift Problem: Why 18 to 22% of Earnouts End in Dispute
Once the deal closes, the buyer owns the business and runs the books. Even a seller with the cleanest revenue-based earnout faces this reality: the buyer is making operating decisions that directly affect the metric. This phenomenon, often called “accounting drift” or “earnout starvation,” is the single largest source of post-closing M&A litigation.
According to SRS Acquiom 2024, 18% to 22% of earnouts in their dataset resulted in a documented dispute or claim by the seller, with a median dispute value of roughly $2.3M and a tail of cases above $50M. Disputes typically arise on one or more of the following patterns.
- Cost reclassification: Buyer reallocates parent-company corporate overhead to the acquired subsidiary, compressing EBITDA.
- Sales channel cannibalization: Buyer routes customers through a parent-company channel rather than the acquired entity, suppressing acquired-entity revenue.
- Investment starvation: Buyer cuts the acquired entity’s marketing, R&D, or salesforce, suppressing growth metrics.
- Accounting policy changes: Buyer changes revenue recognition timing, inventory accounting, or capitalization policy, shifting metric values.
- Customer churn from integration: Buyer’s product integration causes customers to leave, suppressing retention metrics.
- Mid-stream sale or restructuring: Buyer sells the acquired entity or restructures before the earnout period ends.
Two cases are commonly cited as the leading authority on accounting drift in U.S. M&A. The first, Akorn Inc. v. Fresenius Kabi AG (Delaware Court of Chancery, 2018), dealt with material adverse effect (MAE) rather than earnout, but established the Delaware court’s willingness to look closely at buyer post-signing conduct. The second category includes recent Delaware Chancery earnout disputes such as Shareholder Representative Services LLC v. Albertsons Companies and a string of 2023 to 2025 decisions where the court has consistently held that the buyer’s implied covenant of good faith and fair dealing limits its ability to take actions that frustrate the earnout. The Delaware Court of Chancery’s opinions archive is the primary source for current caselaw.
The American Institute of Certified Public Accountants (AICPA) addresses some of this in FASB ASC 805, which requires acquirers to remeasure contingent consideration at fair value at each reporting date, but ASC 805 governs the buyer’s accounting for its balance sheet, not the seller’s right to receive the earnout under the SPA. The two are separate.
Legal Protections Sellers Should Demand
The earnout is a contract. Most accounting drift problems can be prevented at drafting if the seller’s counsel insists on a standard package of protective covenants. The following protections appear in well-drafted SPAs and are documented in standard M&A treatises such as the ABA Model Stock Purchase Agreement with Commentary and Practical Law M&A precedent.
- Express duty of good faith and reasonable efforts: Buyer covenants to operate the acquired business in good faith and to use commercially reasonable efforts to achieve the earnout targets. Without this, sellers fall back on the implied covenant under Delaware law, which is narrower than an express covenant.
- No-change in accounting policy covenant: Accounting policies and practices used to calculate the metric are frozen as of closing and may not be changed without seller consent.
- Operating restrictions: Buyer commits to maintain specified levels of marketing spend, headcount, sales force, R&D, and capital investment.
- No reallocation of corporate overhead: Corporate overhead allocated to the acquired entity is capped at closing-date levels or at a fixed percentage of revenue.
- Anti-stuffing: Buyer cannot stuff the acquired entity with parent-company expenses (legal, finance, HR) that were not previously borne.
- Audit rights: Seller has the right (through an independent third party) to audit the books and records used to calculate the earnout at the buyer’s expense if the audit finds material discrepancy.
- Acceleration on change of control: If the buyer sells, IPOs, or otherwise restructures during the earnout period, the earnout accelerates and pays at the cap (or at a target-based assumed value).
- Dispute resolution mechanism: A clear three-step process: notice, negotiation, then independent accounting firm or arbitration. Litigation should be the last resort.
- Most-favored-nations on disposition: If the buyer divests a portion of the business that contributes to the earnout, the seller is made whole.
Sellers with strong negotiating position can also push for an “earnout floor” (minimum guaranteed payment regardless of performance) and for ratable annual payments rather than a single back-loaded payment.
Tax Treatment of Earnouts: Capital Gain, Ordinary Income, and Imputed Interest
The tax treatment of earnouts is governed primarily by three sections of the Internal Revenue Code: IRC Section 453 (installment sales), IRC Section 483 (imputed interest on deferred payments), and IRC Section 1274 (original issue discount on deferred payments). The interaction of these three sections is complex and is one of the most common areas where sellers and their advisors underestimate the after-tax economics of a deal.
Installment sale treatment under Section 453: When a portion of the purchase price is contingent and deferred, the gain on that portion is generally recognized over the years in which the payments are received, not at closing. This is favorable for sellers because it defers tax liability. The IRS provides guidance in IRS Publication 537 (Installment Sales). Special rules apply when the maximum amount payable is determinable versus when it is not, with the latter creating a more complex basis recovery problem under Treasury Regulation 15A.453-1.
Imputed interest under Sections 483 and 1274: Because the earnout is a deferred payment, the IRS treats a portion of it as interest income (taxed at ordinary income rates) rather than as deferred sale proceeds (taxed at capital gains rates). The applicable federal rate (AFR), published monthly by the IRS at IRS Applicable Federal Rates, is used to compute the imputed interest. In a high-rate environment, this can materially shift the after-tax economics.
Capital gain versus ordinary income (the employment problem): If the earnout is tied to the seller’s continued employment, the IRS may recharacterize the earnout payment as compensation rather than purchase price, converting capital gain to ordinary income and triggering payroll taxes. The leading authority is Lane Processing Trust v. United States and a string of subsequent Tax Court decisions; current treatment is summarized in numerous Tax Notes commentary pieces and in Big Four memos. The standard structural fix is to size the seller’s post-closing employment compensation at fair market value (and document it) so that the earnout itself is not characterized as disguised compensation. This is especially important in acqui-hire deals.
State tax considerations: California, New York, and other high-rate states tax the earnout where the seller is resident in the year of payment, not the year of sale. A founder who sells a business while resident in California and then relocates can face California source-rule complications. See California Franchise Tax Board guidance on installment sales for nonresidents.
2024 and 2025 Earnout Trends
Several trends in earnout structuring have accelerated since 2022, driven by interest rate environment changes, increased PE buyer activity, and the growing prevalence of representations and warranties insurance (RWI). The trends below are documented in SRS Acquiom 2024, Pepperdine PCM Survey 2024, and ABA M&A Committee annual deal point studies.
- Increased usage: The percentage of private-target deals with an earnout rose from roughly 14% in 2017 to roughly 27% in 2023, the highest level recorded in the SRS Acquiom dataset.
- Longer measurement periods: Median earnout period extended from 18 months in 2019 to 24 months in 2023, with 36 months appearing more frequently in technology and software deals.
- More multi-metric structures: The share of earnouts using more than one metric rose from roughly 22% in 2019 to roughly 34% in 2023, with the most common combination being revenue plus EBITDA.
- RWI replacing escrow: Representations and warranties insurance now backs the indemnification cap in roughly 75% of upper-middle-market deals, reducing the need for traditional escrow holdback and pushing more contingent consideration into earnouts.
- PE buyer behavior: PE buyers use earnouts more aggressively than strategic buyers, with median earnout caps of roughly 28% of deal value versus roughly 19% for strategic buyers.
- Higher dispute rates: Disputes have risen alongside usage, with the documented dispute rate climbing from roughly 14% in 2017 to roughly 18% to 22% in 2023.
- More express good faith covenants: The percentage of SPAs containing an express good faith and reasonable efforts covenant rose from roughly 38% in 2019 to roughly 56% in 2023, driven by Delaware caselaw.
Earnout vs Holdback vs Seller Note vs Rollover Equity: Decision Matrix
Earnouts are one of four common deferred-consideration mechanisms in middle-market M&A. They differ in what they protect against and in their risk profile. The matrix below summarizes the differences and helps sellers and buyers decide which structure (or combination) fits the deal.
| Mechanism | What it pays out for | Risk profile for seller | Typical size |
|---|---|---|---|
| Earnout | Post-closing performance against a metric | Performance risk: seller bears it | 10% to 50% of deal value |
| Holdback (escrow) | Indemnification claims for breach of reps and warranties | Contingency risk: only released if no claims | 5% to 15% of deal value (less if RWI used) |
| Seller note | Always-paid debt (subject to default risk only) | Buyer credit risk only; otherwise certain | 10% to 30% of deal value in lower middle market |
| Rollover equity | Continued ownership stake; pays on future exit | Equity risk: tied to buyer’s exit success | 5% to 30% of deal value in PE deals |
Earnout: Pays only if the business hits agreed performance targets. The seller takes performance risk. Best when the gap between buyer and seller is about future performance.
Holdback (escrow): A portion of the purchase price is held in escrow at closing and released to the seller after a defined period (typically 12 to 24 months), subject to indemnification claims. Pays out unless the buyer makes a claim against representations and warranties. With RWI, the holdback is often as low as 1% to 2%. See material adverse effect for related concepts.
Seller note: The seller lends part of the purchase price to the buyer, secured (sometimes) by the business assets. Paid back over time as debt. Carries interest. The seller bears buyer credit risk but not performance risk.
Rollover equity: The seller keeps an ownership stake in the new buyer entity. Common in PE deals where the buyer wants the management team aligned with the buyer’s exit. The seller’s “second bite” depends on the buyer’s exit multiple.
Many deals combine these. A typical PE deal might pay 70% cash at closing, 10% in rollover equity, 5% in escrow, and up to 15% in earnout. The right combination depends on what the parties disagree about and on what risks each party can bear. For more on related structures, see asset sale vs stock sale and M&A advisor.
TLDR and 7 Decision-Stage Takeaways
If you remember nothing else about the earnout definition, remember these seven points before you sit down at the negotiating table.
- 1. Earnout means deferred, contingent purchase price. It is not a bonus, not a holdback, and not a seller note. It pays only if the acquired business hits specified post-closing performance targets.
- 2. The five components are always the same: total pool, metric, measurement period, payout schedule, and cap (with optional floor). Any earnout missing one of these is incomplete drafting.
- 3. Revenue is the cleanest metric. EBITDA is the most common but the most game-able by the buyer. Customer retention works for services; milestones work for pharma.
- 4. The buyer runs the business post-closing. Roughly 18 to 22% of earnouts end in dispute per SRS Acquiom 2024. Build legal protections at drafting, not at litigation.
- 5. Tax treatment is not automatic. Installment sale treatment under IRC 453, imputed interest under IRC 483 and 1274, and the capital gain versus ordinary income question all affect after-tax proceeds.
- 6. Trends favor longer periods and multi-metric structures. Median measurement period is now 24 months (up from 18), and 34% of earnouts use more than one metric.
- 7. Combine instruments thoughtfully. Earnout, holdback, seller note, and rollover equity each protect against different risks. The right deal usually uses two or three in combination.
For the full deep dive on earnout mechanics, sample language, and negotiation playbooks, see the parent earn-out guide. For specific negotiation tactics, see how to negotiate an earnout in a business sale.